Article Text

Download PDFPDF
Specific association of IL17A genetic variants with panuveitis
  1. Arkaitz Mucientes1,
  2. Ana Márquez1,2,
  3. Miguel Cordero-Coma3,
  4. José Manuel Martín-Villa4,
  5. Marina Begoña Gorroño-Echebarría5,
  6. Ricardo Blanco6,
  7. David Díaz Valle7,
  8. José Manuel Benítez-del-Castillo7,
  9. María José del Rio8,
  10. Ana Blanco9,
  11. Jose Luis Olea10,
  12. Yolanda Cordero11,
  13. María José Capella12,
  14. Jacobo Gonzalez13,
  15. Manuel Díaz-Llopis14,
  16. Norberto Ortego-Centeno2,
  17. Alfredo Adán15,
  18. Ioana Ruiz-Arruza16,
  19. Víctor Llorenç15,
  20. Alejandro Fonollosa17,
  21. Javier Martín1
  1. 1Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Granada, Spain
  2. 2Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain
  3. 3Ophthalmology Department, Hospital de León, IBIOMED, Universidad de León, León, Spain
  4. 4Immunology Department, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
  5. 5Ophthalmology Department, Hospital Universitario Principe de Asturias, Alcalá de Henares, Spain
  6. 6Rheumatology Department, Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain
  7. 7Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain
  8. 8Ophthalmology Department, Hospital Carlos Haya, Málaga, Spain
  9. 9Ophthalmology Department, Hospital Donostia, San Sebastián (Guipúzcoa), Spain
  10. 10Ophthalmology Department, Hospital Son Espases, Palma de Mallorca, Spain
  11. 11Ophthalmology Department, Hospital Universitario Rio Hortega, Valladolid, Spain
  12. 12Institut Universitari Barraquer, Universitat Autònoma de Barcelona, Barcelona, Spain
  13. 13Ophthalmology Department, Hospital de la Princesa, Madrid, Spain
  14. 14Ophthalmology Department, Hospital La Fe, Universidad de Valencia, Valencia, Spain
  15. 15Ophthalmology Department, Hospital Clinic, Barcelona, Spain
  16. 16Autoimmune Diseases Research Unit, Internal Medicine Department, BioCruces Health Research Institute, Hospital Universitario Cruces, Barakaldo, Spain
  17. 17Ophthalmology Department, BioCruces Health Research Institute, Hospital Universitario Cruces, Barakaldo, Spain
  1. Correspondence to Dr Ana Márquez, Instituto de Parasitología y Biomedicina López-Neyra. Consejo Superior de Investigaciones Científicas. Parque Tecnológico Ciencias de la Salud. Avenida del Conocimiento s/n 18016-Armilla (Granada), Spain; anamaort{at}


Background/aims A pathogenic role of Th17 cells in uveitis has become clear in recent years. Therefore, in the present study, we aimed to evaluate the possible influence of the IL17A locus on susceptibility to non-anterior uveitis and its main clinical subgroups.

Methods Five IL17A polymorphisms (rs4711998, rs8193036, rs3819024, rs2275913 and rs7747909), selected by tagging, were genotyped using TaqMan assays in 353 Spanish patients with non-anterior uveitis and 1851 ethnically matched controls.

Results The case/control analysis yielded a consistent association between two of the analysed genetic variants, rs8193036 and rs2275913, and the presence of panuveitis under a dominant model (pFDR=2.86E-03, OR=2.26, 95% CI 1.42 to 3.59 and pFDR=0.033, OR=1.83, 95% CI 1.13 to 2.97, respectively). Subsequently, a specific association of both polymorphisms with the diffuse form of the disease was evident in the subphenotype analysis when considering this same genetic model (panuveitis vs posterior and intermediate uveitis: rs8193036, p=0.020; rs2275913, p=0.038). Independent effects of rs8193036 and rs2275913 were observed by conditional regression analysis.

Conclusions Polymorphisms within the IL17A locus show a novel association with panuveitis. Our data agree with the elevated levels of this cytokine that are found in patients with uveitis, supporting a crucial role of Th17 cells in this pathology.

Subtitle Our results clearly evidenced the role of IL17A as a novel genetic risk factor for panuveitis, thus suggesting the implication of Th17 cells in the extensive inflammation of the uveal tract that occurs in this subtype of uveitis.

  • Genetics
  • Immunology
  • Inflammation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Autoimmune uveitis is an inflammatory intraocular process resulting from a loss of tolerance against ocular antigens.1 This condition usually leads to visual impairment and is considered a major cause of blindness worldwide.2 Currently, the classification of these patients is based on the anatomical location of the inflammation: anterior uveitis (AU), the most common; intermediate uveitis (IU); posterior uveitis (PU); and panuveitis or diffuse uveitis.3 In general, AU is frequently secondary to HLA-B27-associated seronegative spondyloarthropathies and has the best visual prognosis of the subtypes of uveitis. By contrast, non-AU (IU, PU and panuveitis) is usually idiopathic and often requires systemic immunosuppressive therapy.4

Non-AU comprises a wide range of clinical phenotypes, including Birdshot chorioretinopathy, pars planitis and sympathetic ophthalmia, among others. It is known that environmental as well as genetic factors are involved in the appearance and development of these disorders. Regarding genetic factors, certain alleles of the HLA region have been strongly associated with their predisposition5–7; however, these alleles do not explain the entire heritability of uveitis and, in recent years, investigations have focused on non-HLA genes.8–10

Interleukin-17A (IL-17A) is characteristically produced by Th17 cells, which play a pivotal role in autoimmune uveitis.11 Interestingly, increased expression of IL-17A has been detected in peripheral mononuclear cells of patients with uveitis.11 Furthermore, a recent study has shown that patients with uveitis present higher serum IL-17A levels compared with controls.12

Taking all of this into account, the aim of this study was to investigate whether polymorphisms of the IL17A gene are associated with susceptibility to non-AU or its clinical subphenotypes.



We included 353 patients with endogenous non-AU and 1851 healthy controls, all of Spanish origin. Uveitis forms associated with systemic immune-mediated diseases, except for Vogt-Koyanagi-Harada (VKH) syndrome, were excluded. Informed written consent from all participants and approval from the local ethical committees were obtained, in accordance with the tenets of the Declaration of Helsinki. The main clinical characteristics of the analysed cohort are shown in table 1. The intraocular inflammation seen in the patients included IU (22.09%), PU (54.68%) and panuveitis (23.23%).

Table 1

Main clinical characteristics of the patients with non-anterior uveitis included in the study


Genomic DNA was extracted from peripheral blood cells and saliva using standard procedures. Five single-nucleotide polymorphisms (SNPs) located within the IL17A gene, which tagged over 86% of the variability of this locus, as described in a previous report,13 were analysed. The SNPs rs4711998, rs8193036, rs3819024, rs2275913 and rs7747909 were genotyped using TaqMan allelic discrimination assays on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, California, USA).

Statistical analysis

The overall statistical power of our study, shown in online supplementary table S1, was calculated using Power Calculator of Genetic Studies 2006 software ( The case–control study was carried out using the Linux software Plink V.1.07 ( The genotype, allele and carrier frequencies were compared between patients, subgroups of patients and controls using the χ2 test and Fisher test, when necessary. ORs and 95% CIs were obtained according to Woolf's method. The Hardy-Weinberg equilibrium (HWE) was tested for all SNPs at a significance level of 0.01. Because different polymorphisms were analysed in the current study, the Benjamini and Hochberg (1955) step-up false discovery rate (FDR) control correction for multiple testing was applied to the p values. p Values lower than 0.05 after FDR correction were considered statistically significant. Conditional logistic regression analysis, as implemented in Plink, was used to test the dependency of the associations between SNPs, and the allelic combinations were tested using Haploview (V.4.2).


No statistically significant deviation from the HWE was observed in cases and controls for any of the tested polymorphisms. The genotyping success rate was higher than 95% for all the analysed SNPs.

Allele and genotype tests

The genotypic and allelic frequencies for the cases and controls are shown in table 2. When the frequencies were compared between patients with non-AU and controls, one of the studied SNPs, rs8193036, was associated with the global disease (pFDR=0.0117; OR=1.33; 95% CI 1.11 to 1.60). Subsequently, patients with non-AU were stratified according to the different clinical features shown in table 1. This subphenotype analysis showed a specific association between this same SNP and panuveitis (table 3; pFDR=4.05E-04; OR=1.95; 95% CI 1.39 to 2.72). Consistently, statistically significant differences were observed when patients with panuveitis were compared with those showing the posterior or intermediate forms of the disease (p=8.15E-03).

Table 2

Genotype and MAFs of the IL17A genetic variants in patients with non-anterior uveitis and healthy controls from Spain

Table 3

Genotype and MAFs of the IL17A genetic variants in patients with uveitis, stratified according to the anatomic classification, and healthy controls from Spain

Finally, when considering the dominant model, significant associations between rs8193036 and both non-AU (pFDR=0.0186; OR=1.41; 95% CI 1.12 to 1.78) and panuveitis (pFDR=2.86E-03; OR=2.26; 95% CI 1.42 to 3.59) were observed. In addition, under this same model, the rs2275913 polymorphism appeared to be associated with panuveitis (pFDR=0.0334; OR=1.83; 95% CI 1.13 to 2.97). Again, the subphenotype analysis showed a specific association between both SNPs and panuveitis (panuveitis vs PU+IU: rs8193036, p=0.020; rs2275913, p=0.038).

Conditional logistic regression

Since two SNPs were associated with panuveitis under the dominant model, we decided to perform a pairwise conditioning analysis to test the possible dependency among them. As indicated in online supplementary table S2, this analysis suggested the existence of two independent signals. A significant association (p=0.0024) was still evident for rs8193036 after conditioning by rs2275913. Likewise, for this last SNP, a trend of association (p=0.0754) was observed after conditioning by rs8193036.

Allele combination analysis

As the two SNPs associated with panuveitis seemed to be independent signals, we carried out an allele combination analysis in patients with panuveitis and controls to verify the existence of an additive effect (see online supplementary table S3). As expected, two of four possible allele combinations showed significant results (see online supplementary table S3): one carrying the risk alleles of the two associated polymorphisms (rs8193036*C-rs2275913*A, pFDR=3.90E-03; OR=1.99; 95% CI 1.34 to 2.94) and the other containing the protective alleles of these SNPs (rs8193036*T-rs2275913*G, pFDR=0.0259; OR=0.66; 95% CI 0.49 to 0.91).


In our study, five IL17A polymorphisms, which tagged most of the genetic variation of this locus, were analysed in a Spanish cohort of patients with uveitis. Our data show, for the first time, a clear role of the IL17A locus in panuveitis susceptibility. Specifically, independent effects of two SNPs, rs8193036 and rs2275913, were observed in this particular subgroup, which was consistent with the several independent signals at the IL17A locus that were recently described in giant cell arteritis (GCA) patients.14 No additive effect of the rs8193036 and rs2275913 polymorphisms was evident, since the effect conferred by the risk haplotype (rs8193036*C-rs2275913*A) (OR=1.99) did not differ substantially from that conferred by the independent polymorphisms (rs8193036: OR=2.26; rs2275913: OR=1.83).

Interestingly, both SNPs have been associated with and seem to have a functional role in different inflammatory diseases. On one hand, consistent with that observed in the present study, the minor allele of the rs8193036 polymorphism was found to confer risk to inflammatory bowel disease (IBD) and Behçet disease (BD) in the Korean population.15 ,16 In addition, this allele correlated with increased IL17A expression in Korean patients with IBD.15 However, it is noteworthy that the minor allele of the rs8193036 genetic variant differs between populations (in the European population, it corresponds to rs8193036*C, whereas in the Asian population, it corresponds to rs8193036*T). Therefore, despite the functional role proposed for rs8193036, no aetiological value can be confidently ascribed to this SNP, which could be acting as a genetic marker in linkage disequilibrium with the real causal variant. On the other hand, the rs2275913 SNP has been associated with rheumatoid arthritis and GCA in European populations.13 ,14 This polymorphism is located within a binding site for the transcription factor NFATC (nuclear factor of activated T cells), which plays a crucial role in regulating IL-17A expression.17 In agreement with the elevated levels of this cytokine that were found in patients with uveitis,11 ,12 it has been described that the rs2275913 risk allele results in a higher affinity of IL-17A for NFATC, which correlates with the increase in IL-17A production.18

Although the aetiology of uveitis is not fully understood, the pathogenesis of autoimmune uveitis seems to be mainly mediated by a T cell-driven immune response.19 Th17 cells release IL-17A, which exhibits potent proinflammatory properties in animal models of autoimmunity, including autoimmune uveitis.11 In line with this, it has been recently shown that treatment with IL-17 blockers reduces the severity of experimental autoimmune uveitis in mice11; however, the efficiency of this therapy for human uveitis is not clear. Although, secukinumab, a monoclonal antibody that neutralises IL-17A, demonstrated efficacy and safety in patients with active non-infectious uveitis in a study by Hueber et al20; a recent study has not confirmed the therapeutic role of blocking this cytokine.21 As indicated by the authors, a possible explanation for these contradictory findings could be that this treatment is only effective in particular subtypes of uveitis. Supporting this idea, our data clearly point to a specific role of IL-17A in patients showing the diffuse form of this disease.

It should be noted that associations between other genes in the Th17 pathway and systemic diseases involving uveitis have been recently identified through genome-wide association studies. Specifically, IL23R (encoding a subunit of the receptor for IL-23, a key cytokine for the development of Th17 cells) appears to participate in VKH syndrome and BD pathogenesis,22–24 while STAT4 (required for the signal transduction of IL-23) has been linked to this latter condition.25 ,26 Interestingly, both diseases are frequently associated with the presence of panuveitis.

In conclusion, our data support a relevant role of the IL17A locus in the genetic susceptibility to panuveitis development, thus suggesting a crucial role of Th17 cells in the mechanism underlying the extensive inflammation of the uveal tract that occurs in this subtype of uveitis. The identification of specific genetic risk factors for panuveitis could lead to improved diagnosis and prognosis of these patients, as well as to the development of more specific and effective therapeutic strategies for the management of this disease subphenotype.


The authors thank Sofía Vargas, Sonia García and Gema Robledo (from the Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, Spain) for their excellent technical assistance and all of the patients and healthy controls for kindly providing their essential collaboration. Banco Nacional de ADN (University of Salamanca, Spain) and Biobanco Vasco para la Investigación (Fundación Vasca de Innovación e Investigación Sanitarias, Bizkaia, Spain) are thanked for supplying a portion of the samples.


Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:


  • AMu and AMá contributed equally.

  • Contributors AMu, AMá, MC-C and JM were involved in the conception and design of the study. AMu and AMá contributed in the analysis and interpretation of data, and drafted the manuscript. MC-C, JMM-V, MBG-E, RB, DDV, JMB-d-C, MJdR, AB, JLO, YC, MJC, JG, MD-L, NO-C, AA, IR-A, VL and AF collected samples and participated in analysis and interpretation of data. MC-C, JMM-V, MBG-E, RB, DDV, JMB-d-C, MJdR, AB, JLO, YC, MJC, JG, MD-L, NO-C, AA, IR-A, VL, AF and JM revised critically the manuscript draft.

  • Funding This study was supported by AbbVie Pharmaceutical. AMá is recipient of a Rio Hortega fellowship (CM13/00314) from the Ministry of Economy and Competitiveness through the Instituto de Salud Carlos III.

  • Competing interests None.

  • Ethics approval The Ethics Committee of each participating centre.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost Jonas